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Evaluation of an outpatient pharmacy collaboration with a hospital
quality initiative to increase access to naloxone at hospital discharge
Melissa Yokoyama, PharmD; Theresa Morikawa, PharmD, MBA, BCACP; Amber Franck, PharmD; and Adam
Saulles, PharmD, CSP, BCACP

Background

Discussion

Naloxone Dispensing Workflow

Results

• Many hospitals and health systems are
responding to the opioid epidemic with
initiatives aimed at reducing opioid-related
morbidity and mortality.
• Unfortunately, many naloxone prescriptions go
unfulfilled due to barriers such as cost or
patient assumptions that naloxone will not be
needed.
• A quality initiative at a large tertiary medical
center takes a unique approach to increasing
patient access to naloxone at hospital
discharge through early prescribing and
naloxone access facilitation by the integrated
outpatient pharmacy team.

Primary Outcome:

Dispensed rates
Secondary Outcomes:

% hospital charity used
% orders sent before
discharge date
% dispensed before
discharge date

•
•

This initiative was implemented at a large tertiary
medical center on January 13th, 2022 with the
goal of increasing patient access of naloxone at
discharge.

Naloxone Dispensed Rates

78%

0.41

PreImplementation
(n= 135)
3% (4)

PostImplementation
(n= 146)
12% (17)

P-value

28% (38)

41% (60)

0.0247

6% (8)

25% (37)

0.0001

0.0060

Patient Population
The pilot project went live January 13th, 2022.
A total of 281 (pre-implementation N=135, postimplementation N=146) naloxone orders were included
and reviewed over the 18-week study timeline.

• While primary outcome statistical significance was not
achieved, positively trending outcomes demonstrate
that patients prescribed opioids being discharged from
the acute setting would benefit from the continuation of
this quality initiative through increased access to
naloxone
Limitations
• Select data was pulled from EHR by single reviewer
• Short study time frame with small sample size
• Given recent protocol implementation, there was no
washout period
• Unable to determine access when outside pharmacy
was utilized
• Single-centered study
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% of Naloxone Orders
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Post-Implemetation

Going Forward

% Naloxone Orders In Which Hospital Charity Was Used
% of Naloxone Orders

Methods
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Pre-Implementation

Post-Implemetation

35.00%

33.33%

30.00%

31.48%

Average copay: $31.23

25.00%

20.37%

20.00%

14.81%

15.00%
10.00%
5.00%
0.00%
$1-$5

$6-$15

$16-$45

>$46

Investigate potential for pharmacy to assist with
proactive naloxone prescribing during inpatient
admissions
Develop an EHR-driven alert to increase appropriate
prescribing of naloxone in advance to discharge
Continue to study the timing of naloxone orders in
relation to discharge and dispense rates
Conduct further study to evaluate the dispense rates
between pharmacist and hospitalist-prescribed naloxone

References

Average Copay Amount Over The 18 Week Study Period*
% Of Naloxone Orders

• IRB Status
• Approved
• Study design
• Single-centered, retrospective chart review preand post-implementation study
• Study Timeline
• Pre-intervention: 11/11/2021 to 1/12/2022
• Post-intervention: 1/13/2022 to 3/17/2022
• Inclusion criteria
• Inpatient admissions to the large tertiary medical
center
• Patients discharging with a prescription for
naloxone from onsite outpatient pharmacy
• Patients ≥ 18 years or older
• Statistics
• Fisher’s exact test used to determine statistical
significance
• P-value <0.05 is considered statistically significant

P-value

• Initial data showed statistical significance for hospital
charity utilization, percent of naloxone orders sent prior
to discharge and percent of naloxone dispensed prior to
discharge date.

Graphs 1-3 Study Outcomes

Objectives

Secondary outcomes
• Percent of naloxone orders in which hospital
charity was used
• Percent of naloxone orders sent before discharge
date
• Percent of naloxone orders dispensed before
discharge date
• Copay amounts of naloxone over 18 week study
period

PostImplementation
(n= 146)
77% (113)

Clinical Outcomes
• After implementation of the quality initiative, the
number of dispensed naloxone prescriptions increased
as observed through the dispense rates but did not
achieve statistical significance.

Purpose
• To evaluate the impact of this quality initiative
on patient access to naloxone after inpatient
hospital admission prior to discharge

Primary outcome
• Naloxone dispensed rates pre- and postimplementation

PreImplementation
(n= 135)
73% (98)

*among patients
with a copay
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